# Hoffmann-La Roche: Phase 3 study closed enrollment, 382 enrolled (Cancer)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) |
| NCT ID | NCT03148418 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Cancer |
| Intervention types | drug |
| Target enrollment | 382 |
| Site countries | United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Czechia, France, Germany |
| Posted | 2017-05-11 |
| Planned start | 2017-09-20 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-08 |
| Last update posted | 2026-10-08 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 382 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT03148418). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.